Pharma companies Novavax, Moderna, and GSK all have RSV vaccines in the pipeline
Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, the Food and Drug Administration (FDA) put a clinical hold on the combination and standalone influenza shot developed by Novavax Inc (NASDAQ:NVAX).
NVAX Testing Chart Support
NVAX is down 17.7% to trade at $10.36 in response, on track for its lowest close since mid May. The shares are still up 115% in 2024 though, and the round-number $10 level -- an area that coincides with its 160-day moving average -- could be a pivot point to watch.
Moderna Waiting for 2025
Sector peer Moderna Inc (NASDAQ:MRNA) was last seen trading at $57.42, a chip shot from its Oct. 11 four-year low of $55.70. The shares have taken a 42.2% haircut year-to-date, aided in large part by a 12.4% gap lower on Sept. 12, after the pharma company slashed its budget and scaled back its own RSV drug expectations. At the investor conference, Moderna CEO Stéphane Bancel expected to regain more RSV market share RSV in 2025.
Don't Forget About GSK
London-based GSK (NYSE:GSK) is up 0.5% to trade at $39.17, after the FDA accepted its new drug application for urinary tract infections (UTIs). Back in the summer, the FDA also approved the company's RSV vaccine, though the stock didn't react much. The shares are 5.8% higher in 2024.